Marcelo Corassa, MD.
@MarceloCorassa
Husband, Father. Medical Oncologist and Researcher focused in Thoracic Oncology. Views are my own.
What about the rare stuff? @BRicciutiMD sheds light in what to do in patients with AGAs that could potentially respond to IO, such as MET, BRAF and KRAS. And it would not be Biagio without an opinion on STK11/KEAP1 co-mutations. #ASCO25
What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line ! We look forward to seeing the final OS data... #EGFR #lungcancer
🎥@MarceloCorassa hares Phase I/II SOHO-01 trial updates on BAY 2927088 in HER2-mutant NSCLC. Consistent responses, manageable safety, diarrhea most common AE, no lung toxicity seen: 🔗 ow.ly/pOEn50WgglL @ASCO #ASCO25 #LCSM #LungCancer #NSCLC #HER2
~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In @NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/
Amazing work, Alessandro. This poster has the power to change our view on those patients. You rock!
Many thanks to @VJOncology for featuring our study comparing immunotherapy to BRAF and MEK inhibitors for the first-line treatment of patients with BRAF V600E mutant NSCLC @IASLC @myESMO @BRicciutiMD @mvnegrao @DanaFarber @MDAndersonNews @MSKCancerCenter vjoncology.com/video/wgsujs7x…
With the best at #ASCO25 Last day and then Boston and/or Italy And our Brazilian transplant Dr. @MarceloCorassa Early stage session with a focus on target mutations
Burning question. Are you comfortable with omitting adjuvant platinum-based chemotherapy in ALK positive patients as per the design of the ALINA trial? @BRicciutiMD @kaushalpar @CharuAggarwalMD
#ASCO25 @ASCO Education Book has incredible resources in #LungCancer #LCSM Super proud of an amazing team of fellows mentored by @kaushalpar @BiagioRicciutMD and me! @BenBleibergMD @tejavoruganti So much going on in this space - especially with #NeoADAURA being presented,…
What about ALK? @kaushalpar presents a comprehensive insight on this population. For me, it is a proof of concept for all fusions that we should not pursue chemoIO in any setting. #ASCO25
Great talk by the amazing @CharuAggarwalMD about definition of curative therapy in patients with "common" AGAs, in other words, EGFR/ALK. We are still trying to understand exactly TKIs are going to fit in patients candidates to surgery. #ASCO25
Don't lose the opportunity to see @BRicciutiMD in a suit and a tie here at Room E450a. A last push in the last day of this amazing #ASCO25
Dr. @charlesrudin confirming what DeLLphi-301 brought to light. Could say a lot of things, but Tarla provided a better OS in second line after chemo than chemo + durva/atezo. 13.6 x 8.3 months! PFS 5.3 x 4.3, but with a sign for long-term benefit for 20% of patients. #ASCO25
Not only BIspecific. Now we’re going TRIspecific. Alvetamig, targeting CD3/DLL3/DLL3 (distinct DLL3 epitopes) in after at least 2 prior lines of therapy is safe, consistent with the drug class. Small number of its, but over 50% ORR. DoR still not mature. #ASCO25
IMforte, presented by Dr. Paz-Ares, shows benefit with Lurbi + Atezo as maintenance after chemo + Atezo. Gain in OS (13.2 x 10.6 mo, HR 0,0174) and PFS (5.2 x 2.1 mo, HR 0.54). My point, this benefit will be considered significant after the DeLLphi-305 is presented? #ASCO25
Now it is time for SMALL cell lung cancer go BIG with the last oral presentations of today’s session. But! Such a bummer that we got spoilers with the @NEJM publication this morning. It took away all the thrill! #ASCO25
Did anyone see @NarjustFlorezMD today? I have to return her makeup purse. I cannot keep walking with all this expensive Chanel products in my backpack. Just for clarification, she forgot it and at least for now I am still not using any kind of makeup 😂😂😂
There is a Brazilian saying that states: “Deus ajuda, quem cedo madruga”. In other words, God helps those who wake up early. And this may really play a role for IO, with prospective data, also demonstrating that circulating T cell profile also changes. #ASCO25
Morning > Afternoon for IO? Evidence is mounting—retrospective and now prospective (210 pts, randomized, PFS HR 0.42 but no PD-L1 strat). Given IO’s long half-life, maybe only the timing of the first dose matters. #ASCO2025
Plasma-guided intensification from 1L pembro ➡️ chemo+pembro is feasible ▫️mPFS of 11.0 mos with fewer patients needing upfront chemo than PD-L1 TPS alone would suggest ▫️ctDNA kinetics = promising dynamic biomarker for guiding tx ▫️Needs RCT validation #ASCO25 @JuliaRotow
‼️PD-L1 is an imperfect biomarker—could cfDNA dynamics guide early treatment decisions in NSCLC? In this plasma-guided approach, 17.5% received upfront chemo v 37.5% predicted by PD-L1 status alone—suggesting cfDNA clearance may help refine treatment intensification. #ASCO25
Dr. @JuliaRotow of @DFarberThoracic Plasma-guided intensification from 1L pembro to chemo+pembro in PD-L1+ metastatic NSCLC. mPFS was 11 mo. Further validation needed but opportunities here to spare pts from chemo. @ASCO #ASCO25 #lcsm #lcam
Amazing community 🫁!! Thank you @marinagarassino for your kindness & hospitality! Amazing people @NarjustFlorezMD @StephenVLiu @DrSanjayPopat @HwakeleeMD @HosseinBorghaei @MarceloCorassa . and many others!! #ASCO2025 #lungcancer #iaslc